on Revolune
Revolune GmbH Launches to Advance Spatial Biology
Oberkochen, Germany - April 15, 2026: Revolune GmbH, a new life science company, officially launches to simplify spatial biology studies. They specialize in streamlined multiplex immunofluorescence (mIF) reagents, enhancing tissue analysis workflows for translational and biopharma research.
Today's biomedical research increasingly relies on spatially resolved biomarker analysis. Traditional multiplex tissue workflows often face technical challenges, hindering broader adoption. Revolune aims to overcome these barriers by providing reagent solutions that enhance clarity and efficiency in tissue analysis.
CEO Florian Leiss emphasizes their mission to "illuminate what matters," focusing on reducing workflow complexity. Leiss, formerly with ZEISS, brings substantial experience in spatial biology. Alongside him, Michaeli Deli joins as CFO to guide Revolune's strategic growth. The company's Early Access Program invites collaboration on developing advanced spatial biology workflows.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Revolune news